SCHEMBL1753716

SCHEMBL1753716

CC(C)c1ccon1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119618 0.80 LMNA (0.33)
SCHEMBL11400000 0.80
SCHEMBL841687 0.80
SCHEMBL14738349 0.80
SCHEMBL1639903 0.80
SCHEMBL9963716 0.78
SCHEMBL24050466 0.77 NPC1 (0.34)
SCHEMBL19601418 0.77
SCHEMBL19608177 0.75
SCHEMBL22096764 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 793 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612409-B2 Pyrrolopyrimidines as CFTR potentiators CYSTIC FIBROSIS FOUNDATION (US) 2026-04-28 US disclosed
US-12552765-B2 Small molecule modulators of pantothenate kinases ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. 2026-02-17 US disclosed
US-12552755-B2 Cinnamic amide derivative having FXR activating effect, pharmaceutical composition containing the same as active ingredient, and method for preparing the same KYUNGSUNG UNIVERSITY INDUSTRY COOPERATION FOUNDATION (KR) 2026-02-17 US disclosed
EP-3731859-B1 PYRIDAZINE COMPOUNDS FOR USE TO TREAT DISORDERS ASSOCIATED WITH CASTOR ST JUDE CHILDRENS RES HOSPITAL INC (US) 2025-08-20 EP disclosed
US-20250090526-A1 METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. 2025-03-20 US disclosed
US-12202826-B2 N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway REDX PHARMA PLC (GB) 2025-01-21 US disclosed
US-12194031-B2 Compounds for use in regulating follicle maturation AARHUS UNIVERSITET (DK) 2025-01-14 US disclosed
US-20250002487-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2025-01-02 US disclosed
CN-111787939-B Methods of treating CASTOR-related disorders 圣朱德儿童研究医院有限公司 2024-09-13 CN disclosed
US-20240239811-A1 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T REMIX THERAPEUTICS INC. 2024-07-18 US disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 US disclosed
US-20070082908-A1 Bicycle pyrazole derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-12 US disclosed
US-20070082908-A1 Bicycle pyrazole derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-12 US disclosed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US disclosed
US-7163951-B2 N-biarylmethyl aminocycloalkanecarboxamide derivatives MERCK & CO., INC. (US) 2007-01-16 US disclosed
US-7157476-B2 Aminofurazan compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-01-02 US disclosed
EP-0046193-B1 1-HYDROXYPYRAZOLE AND PROCESS FOR PREPARING THE SAME BASF Aktiengesellschaft (DE) 1983-09-28 EP disclosed
US-4350819-A 1-Hydroxypyrazole BASF AKTIENGESELLSCHAFT (DE) 1982-09-21 US disclosed
US-4337188-A POLYMERIC BLENDS FOR PACKAGING DU PONT CANADA INC. (CA) 1982-06-29 US disclosed
EP-0046193-A1 1-Hydroxypyrazole and process for preparing the same BASF Aktiengesellschaft (DE) 1982-02-24 EP disclosed